Advertisement
SION vs TENX
Which Stock Would AI Choose? Sionna Therapeutics (SION) vs. Tenax Therapeutics (TENX) Stock Comparison
Key Takeaways
- Both SION and TENX are pre-revenue, development-stage biopharmaceutical companies that have each absorbed sharp share-price declines following clinical setbacks.
- SION lost roughly 90% of its value after its lead cystic fibrosis candidate missed its primary endpoint in a Phase 2a trial, triggering a restructuring and pivot to a dual-combination program.
- TENX has also retreated sharply over the past year as investors reassess its cardiopulmonary pipeline, despite a debt-free balance sheet and substantial cash relative to its market capitalization.
- Neither name generates revenue, so relative performance is driven primarily by clinical catalysts, cash runway, and sentiment rather than fundamentals such as earnings or sales.
- Both stocks carry elevated risk profiles, though their cash positions and pipeline optionality differ meaningfully in terms of downside cushion and near-term catalysts.
- For more detail, review SION Major News and SION Today's Price Move, as well as TENX Major News and TENX Today's Price Move.
- To see which names automated systems currently favor, explore Trending AI Robots.
Introduction
Investors evaluating small-cap biotechnology often weigh clinical risk, balance-sheet strength, and market positioning above all else. SION (Sionna Therapeutics) and TENX (Tenax Therapeutics) sit squarely in this category: both are development-stage pharmaceutical companies without approved products or revenue, and both have seen their share prices reset sharply in recent months. This stock comparison is most relevant for traders and investors who follow binary clinical events, monitor cash runway closely, and seek to understand how two post-selloff biotech names differ in catalysts, sector exposure, and relative performance. The sections below examine each company's recent behavior and market positioning.
SION Overview and Recent Performance
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on cystic fibrosis (CF), developing small-molecule therapies designed to normalize the function of the CFTR protein. Its lead program, the NBD1 (nucleotide-binding domain 1) stabilizer SION-719, suffered a major setback in recent months when a Phase 2a proof-of-concept trial added to standard-of-care therapy failed to meet its key endpoint measuring sweat chloride reduction. The announcement triggered a decline of roughly 90% in a single session, and the shares have remained under pressure in the weeks since.
In response, the company announced a restructuring that reduced its workforce by approximately 46% and pivoted its strategy toward a dual-combination program pairing SION-451 with SION-2222 (galicaftor), with a Phase 2a trial planned for 2027. Sionna reported about $268 million in cash and marketable securities as of mid-2026, providing a relatively long runway. A securities-law firm has also disclosed an investigation into the company, adding a layer of overhang to sentiment.
TENX Overview and Recent Performance
Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary diseases with high unmet need, primarily pulmonary arterial hypertension (PAH) and heart failure with preserved ejection fraction (HFpEF). Its pipeline centers on TNX-201 (an oral imatinib formulation) and TNX-103 (oral levosimendan). The shares have declined sharply over the trailing twelve months, reflecting a broader repricing of the company's clinical prospects following a pivotal trial miss that has shifted the narrative toward future trials in a more targeted patient population.
Despite the price weakness, Tenax maintains a debt-free balance sheet with cash exceeding its market capitalization, a profile that distinguishes it from many peers in its valuation range. The company continues to advance its levosimendan program in PH-HFpEF, though near-term sentiment remains cautious as investors await clarity on trial design and data timing. The stock's micro-cap status and concentrated pipeline contribute to its high volatility.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies drawn from hundreds of AI trading bots that collectively monitor thousands of tickers. Each bot operates with its own trading style, strategy, timeframe, performance history, and universe of tickers, but only those best suited to current market conditions earn a place in this featured section. This filtering helps traders identify strategies aligned with today's volatility and momentum rather than relying on a one-size-fits-all approach. For investors tracking names like SION and TENX, exploring the Trending AI Robots page can offer a data-driven lens on how systematic models interpret shifting conditions.
Head-to-Head Comparison
The most immediate contrast between these two names is therapeutic focus. SION operates in cystic fibrosis, a space long dominated by established modulator therapies, while TENX targets cardiovascular and pulmonary disease with a Phase 3-stage pipeline. Both face binary, data-dependent risk, but their positioning differs: Sionna's value now rests on an earlier-stage dual-combination program, whereas Tenax retains later-stage assets that have already demonstrated signals in select patient subgroups.
On balance-sheet strength, both companies hold meaningful cash relative to their market values, though Tenax's net cash position exceeds its market capitalization, while Sionna's larger absolute cash balance funds a broader research effort. Sentiment has been negative for both, but the drivers differ: Sionna's decline was tied to a single failed efficacy readout and an active securities investigation, while Tenax's slide reflects a more gradual reassessment of a pivotal miss. Risk factors include dilution risk, clinical failure, and regulatory uncertainty for both, with Sionna facing the added overhang of litigation-related headlines.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely view TENX as the relatively more stable candidate in the current environment, primarily because its decline has been more gradual and its balance sheet offers a stronger cushion relative to market capitalization. However, this edge is probabilistic rather than definitive: SION retains a larger cash balance and a clearly defined near-term catalyst in its dual-combination program, which could support a sentiment rebound. Neither stock currently exhibits the trend consistency or positive momentum that systematic models typically favor, so the verdict hinges on stability and risk-adjusted positioning rather than confirmed directional strength.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SION is a Hold and TENX is a Hold.
SION in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026
SION may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 9 of 10 cases where SION's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where SION advanced for three days, in 99 of 115 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SION declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for SION entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.558) is normal, around the industry mean (3.498). P/E Ratio (-1.526) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. SION’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SION’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TENX in -11.41% downward trend, sliding for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TENX declined for three days, in 311 of 358 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 37 cases where TENX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TENX as a result. In 79 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
TENX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The Aroon Indicator for TENX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TENX's RSI Oscillator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +2.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where TENX advanced for three days, in 191 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TENX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.557) is normal, around the industry mean (3.498). P/E Ratio (-1.142) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. TENX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TENX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TENX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 92 | |
P/E GROWTH RATING 1..100 | 98 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| SION | TENX | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 78% | 4 days ago 79% |
| Stochastic ODDS (%) | 4 days ago 89% | 4 days ago 81% |
| Momentum ODDS (%) | N/A | 4 days ago 87% |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 4 days ago 83% | 4 days ago 88% |
| TrendMonth ODDS (%) | 4 days ago 81% | 4 days ago 88% |
| Advances ODDS (%) | 13 days ago 86% | 7 days ago 82% |
| Declines ODDS (%) | 7 days ago 84% | 5 days ago 87% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 58% | 4 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SION’s FA Score shows that 2 FA rating(s) are green while TENX’s FA Score has 0 green FA rating(s).
- SION’s FA Score: 2 green, 3 red.
- TENX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SION’s TA Score shows that 4 TA indicator(s) are bullish while TENX’s TA Score has 3 bullish TA indicator(s).
- SION’s TA Score: 4 bullish, 2 bearish.
- TENX’s TA Score: 3 bullish, 5 bearish.
Price Growth
SION (@Biotechnology) experienced а -15.25% price change this week, while TENX (@Biotechnology) price change was -5.59% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
TENX is expected to report earnings on Apr 01, 2027.
Industries' Descriptions
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
SION and
Correlation & Price change
A.I.dvisor indicates that over the last year, SION has been closely correlated with TENX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if SION jumps, then TENX could also see price increases.
| Ticker / NAME | Correlation To SION | 1D Price Change % | ||
|---|---|---|---|---|
| SION | 100% | N/A | ||
| TENX - SION | 93% Closely correlated | +3.68% | ||
| PLRX - SION | 43% Loosely correlated | -0.75% | ||
| MGTX - SION | 42% Loosely correlated | +5.76% | ||
| HRTX - SION | 41% Loosely correlated | +4.64% | ||
| BCAX - SION | 40% Loosely correlated | +5.62% | ||
More | ||||
TENX and
Correlation & Price change
A.I.dvisor indicates that over the last year, TENX has been closely correlated with SION. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if TENX jumps, then SION could also see price increases.
| Ticker / NAME | Correlation To TENX | 1D Price Change % | ||
|---|---|---|---|---|
| TENX | 100% | +3.68% | ||
| SION - TENX | 93% Closely correlated | N/A | ||
| AVXL - TENX | 47% Loosely correlated | +3.60% | ||
| CORT - TENX | 41% Loosely correlated | +1.59% | ||
| HRTX - TENX | 40% Loosely correlated | +4.64% | ||
| MGNX - TENX | 32% Poorly correlated | +4.95% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AMZA | 45.35 | 0.59 | +1.32% |
| InfraCap MLP ETF (AMZA) | |||
| AMZW | 34.63 | -0.04 | -0.13% |
| Roundhill AMZN WeeklyPay ETF | |||
| EQWL | 129.48 | -0.43 | -0.33% |
| Invesco S&P 100 Equal Weight ETF (EQWL) | |||
| MZZ | 6.62 | -0.06 | -0.84% |
| ProShares UltraShort MidCap400 (MZZ) | |||
| EFFE | 23.89 | -0.68 | -2.78% |
| Harbor Osmosis Emerging Markets Resource Efficient ETF | |||